Integrated Care Management for Lupus
(Rheum-iCMP Trial)

Recruiting in Palo Alto (17 mi)

Overseen byCandace H Feldman, MD, ScD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Brigham and Women's Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?

The aim of this study is to identify lupus patients receiving care at Brigham and Women's Hospital (BWH) who are at high risk for potentially avoidable acute care utilization, inconsistent ambulatory care use, and adverse outcomes. The investigators will invite high-risk lupus patients to participate in an intensive care management program with a nurse manager, and will determine whether this program improves receipt of high quality sustained outpatient care and reduces avoidable emergency department visits and hospitalizations. The investigators will also study the social determinants that contribute to acute care use and avoidable outcomes among lupus patients using semi-structured interviews and a photovoice method.

Research Team

Candace H Feldman, MD, ScD

Principal Investigator

Brigham and Women's Hospital

Eligibility Criteria

This trial is for lupus patients at Brigham and Women's Hospital who've had a hospital visit or missed an appointment in the last 3 years, get their primary care there, and meet specific lupus diagnosis criteria. It's not open to those who don't speak English or Spanish.

Inclusion Criteria

Over the preceding 3 years, at least 1 hospitalization or ED visit related to lupus OR at least 1 rheumatology appointment no-show or same-day cancellation

Receive their primary care at BWH

You have been diagnosed with systemic lupus erythematosus (SLE) by a rheumatologist, based on specific criteria set by the American College of Rheumatology.

Exclusion Criteria

Non-English or Spanish speaker

Treatment Details

Interventions

Rheum iCMP (Behavioral Intervention)

Trial OverviewThe study tests an intensive care management program (Rheum iCMP) involving a nurse manager for high-risk lupus patients. The goal is to see if it improves regular outpatient care and reduces unnecessary emergency visits and hospital stays.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Rheum iCMP Wave 2Experimental Treatment1 Intervention

20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months

Group II: Rheum iCMP Wave 1Experimental Treatment1 Intervention

20 patients enrolled immediately in Rheum iCMP